Response to trametinib of histiocytosis with an activating <i>PTPN11</i> mutation
Laure Farnault(Aix-Marseille Université), Jean-François Emile(Université de Versailles Saint-Quentin-en-Yvelines), S. Gabriel(Hôpital de la Timone), Jean Donadieu(Sorbonne Université), Lénaïg Mescam(Institut Paoli-Calmettes), Raphaëlle Fanciullino(Centre National de la Recherche Scientifique), Julien Haroche(Inserm), Geoffroy Venton(Inserm), Zofia Hélias‐Rodzewicz(Université de Versailles Saint-Quentin-en-Yvelines)
Cited by 2
Related Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
B cell–helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen
|Nature Immunology|2011|724
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
|Journal of Allergy and Clinical Immunology|2017|316
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298